Black Diamond Therapeutics. Every tracked FinTwit mention of $BDTX, newest first. 16 mentions since the first on Dec 3, 2025. See the price chart.
May 2026 · 7 mentions
May 22
Jacob Plieth — $BDTX opens off 20%. Here's why, via @ApexOnco -> https://t.co/Ep7ssF1uTy #ASCO26↗
May 22
Jacob Plieth — @Miljenkoz "Not the best." Yes, that's one way to put it $BDTX #ASCO26 https://t.co/URArM4awgw↗
May 22
Jacob Plieth — @avidresearch The fact tox has forced $BDTX to take 150mg (instead of 200mg) forward is not good.↗
May 22
Jacob Plieth — @BiotechCLin Indeed. And this concerns 200mg, which is no longer relevant. Expect 150mg to do worse $BDTX↗
May 22
Jacob Plieth — Looks like tox is the biggest worry now for silevertinib. 60% gr3 TRAE for the 200mg dose tested. $BDTX now hoping to take 150mg into registrational trial #ASCO26↗
May 22
Jacob Plieth — Cross-trial mPFS comparison for $BDTX is $AVBP, which clailmed 16.0 months in 1st-line PACCm patients at #WCLC25.↗
May 22
Jacob Plieth — $BDTX old & updated waterfalls from silevertinib study in 1st-line NSCLC with non-classical mutations, at #ASCO26. ORR 60% is unchanged vs Dec 2025. mPFS 15.2mth is newly discl…↗
December 2025 · 9 mentions
Dec 5
Jacob Plieth — Now $ORIC goes after $AVBP & $BDTX in 1st-line PACC lung cancer, and shows why it abandoned relapsed HER2 ex20. Via @ApexOnco -> https://t.co/valRcL0Fvd https://t.co/AITjRMe…↗
Dec 3
Jacob Plieth — $BDTX currently off 17% (earlier -30%) on yet another strategic pivot. @ApexOnco take on today's silevertinib data https://t.co/gaR3OPzVPM $AVBP↗
Dec 3
Jacob Plieth — @Ozymand36063774 @LionsWatson The promising setting (NSCLC) $BDTX can't afford to fund, so instead it's funding pivotal development in GBM, where silevertinib has yet to show any m…↗
Dec 3
Jacob Plieth — @LionsWatson ...but do feel free to use this as a "buying opportunity" LOL $BDTX https://t.co/jLHr5J7gCh
Jacob Plieth — @LionsWatson I'm so sorry for being insufficiently enthusiastic with my praise for $BDTX. Anyway, here's $AVBP https://t.co/ldDzAdxPGc↗
Dec 3
Jacob Plieth — @ErikOtto2 $BDTX ORR in non-classical, non-PACC EGFR mutations seems to be 67% (12/18), according to my calc https://t.co/Hi1kdUISTP↗
Dec 3
Jacob Plieth — Silevertinib in 1L NSCLC non-classical mutations. Data look decent, but $BDTX needs a partner to fund pivotal development https://t.co/0MmOHChwdB↗
Dec 3
Jacob Plieth — ...or is this the regulatory update: no accelerated pathway, needs pivotal trial, and $BDTX can't run this without a partner.↗
Dec 3
Jacob Plieth — I thought we were expecting $BDTX to reveal what regulatory pathway it's planning for silevertinib.↗